HomeInsightsStock Comparison

Lupin Ltd vs Marksans Pharma Ltd Stock Comparison

Lupin Ltd vs Marksans Pharma Ltd Stock Comparison

Last Updated on: May 01, 2025

Key Highlights

  • The Latest Trading Price of Lupin Ltd is ₹ 2094 as of 30 Apr 15:30.
  • The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 36.04% over 5 years.
  • The Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 6867 crore on March 2024 . This represents a CAGR of 64.57% over 5 years.
  • The revenue of Lupin Ltd for the Dec '24 is ₹ 5821 crore as compare to the Sep '24 revenue of ₹ 5715 crore. This represent the growth of 1.86% The revenue of Marksans Pharma Ltd for the Dec '24 is ₹ 709.7 crore as compare to the Sep '24 revenue of ₹ 652.98 crore. This represent the growth of 8.69%.
  • The ebitda of Lupin Ltd for the Dec '24 is ₹ 1409 crore as compare to the Sep '24 ebitda of ₹ 1382 crore. This represent the growth of 1.95% The ebitda of Marksans Pharma Ltd for the Dec '24 is ₹ 166.61 crore as compare to the Sep '24 ebitda of ₹ 146.74 crore. This represent the growth of 13.54%.
  • The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 858.86 crore over 7 quarters. This represents a CAGR of 44.07% The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 105.07 crore over 7 quarters. This represents a CAGR of 25.67% .
  • The Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 20.33 % on March 2024 . This represents a CAGR of 13.49% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

Lupin Ltd News Hub

News

Lupin announces board meeting date

Lupin will hold a meeting of the Board of Directors of the Company on 14 May 2025. Powered...

Read more

30 Apr 2025 11:10

News

Lupin receives USFDA approval for Tolvaptan Tablets

 Lupin has received approval from the United States Food and Drug Administration (U.S. FDA...

Read more

24 Apr 2025 11:06

News

Lupin rallies after receiving USFDA nod for Tolvaptan tablets

The drug is bioequivalent to Jynarque' Tablets by Otsuka Pharmaceutical Company. Lupin is ...

Read more

24 Apr 2025 11:40

News

Lupin gets EIR from USFDA for Nagpur facility

The EIR was issued following an inspection of the facility conducted from 10 June to 13 Ju...

Read more

17 Apr 2025 15:00

News

Lupin allots 24,101 equity shares under ESOP

Lupin has allotted 24,101 equity shares under ESOP on 21 March 2025. In view of the above,...

Read more

21 Mar 2025 16:10

News

Nanomi wins prestigious CMO Award for Life Science Leadership in Drug Delivery

Nanomi B.V., a Dutch subsidiary of the global pharma major Lupin, today announced that it ...

Read more

21 Mar 2025 19:12

Marksans Pharma Ltd News Hub

News

USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York

Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection wa...

Read more

28 Apr 2025 12:58

News

Marksans Pharma gains as USFDA concludes inspection at New York unit

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturi...

Read more

28 Apr 2025 11:56

News

Marksans Pharma's Goa facility receives Australian TGA approval

Marksans Pharma announced that its manufacturing facility located at Plot A-1, Phase 1-A, ...

Read more

20 Mar 2025 15:52

News

Marksans Pharma rises after receiving regulatory nod for supplying pharma products to Australia

The pharmaceutical formulations include solid dosage forms of tablets and hard capsules. T...

Read more

20 Mar 2025 11:22

News

Relonchem receives UK MHRA marketing authorization for Baclofen 10 mg Tablets

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

19 Mar 2025 20:11

News

Marksans Pharma gains after arm gets nod for Baclofen tablets from UK MHRA

Baclofen Tablets are used to help relax specific muscles in the body, providing relief fro...

Read more

19 Mar 2025 12:50

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Lupin Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Lupin Ltd or Marksans Pharma Ltd?

Market cap of Lupin Ltd is 95,634 Cr while Market cap of Marksans Pharma Ltd is 9,924 Cr

What are the key factors driving the stock performance of Lupin Ltd and Marksans Pharma Ltd?

The stock performance of Lupin Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Marksans Pharma Ltd?

As of May 1, 2025, the Lupin Ltd stock price is INR ₹2094.65. On the other hand, Marksans Pharma Ltd stock price is INR ₹219.0.

How do dividend payouts of Lupin Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Lupin Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions